Open Targets Genetics

Daniel studied genetics at Queen Mary University of London (BSc) before attending Cambridge to complete his MPhil in Epidemiology. As a bioinformatician his research has involved looking at how gene and protein expression data can be leveraged to better understand breast and ovarian cancer.

As a computational biologist within the Open Targets Genetics team, his work involves the incorporation of new data sources and analyses to assist in drug target discovery.

Ricardo Esteban Martinez Osorio is a full stack developer working across the Open Targets Platform and Genetics teams.

Jack has a background is in mathematics (BSc) and computational biology (MPhil). His PhD project was focused on the functional genomics of Rheumatoid arthritis, exploring cell-type specific functions underlying existing GWAS associations.

As a statistical geneticist in the Open Targets Genetics team, Jack currently focuses on developing and integrating tissue enrichment analysis for all publicly available GWAS into the Genetics portal.

Szymon studied at Lodz University of Technology (BEng). He started his professional carrier in Children’s Health Memorial Institute in Warsaw where he was working on the rare diseases treatment in Polish population.

Since 2021 he worked as a software developer and bioinformatician in multiple start-ups focused on drug target discovery, whole genome sequencing and clinical trials validation. As a bioinformatician his work involved looking over the connections between co-linked gene mutations and providing predictions on gene functionality.

As a senior computational biologist within the Open Targets Szymon is considered to be a bridge between the Genetics and Data teams to support and lead the development and implementation of the Open Targets Genetics pipelines for drug discovery and target prioritisation.

Yakov obtained his PhD in Statistical Genetics from Novosibirsk State University. He worked on the developing approaches for studying non-additive models and applied them to study the genetics of human metabolome.

In 2018, Yakov became a group lead in the Institute of Cytology and Genetics SB RAS. His research focus was the development of new multivariate approaches and rare variant analysis approaches and its application to study the genetics of human lifespan, back pain and varicose veins.

Yakov joined Open Targets in 2022 as a senior statistical geneticist in the Genetics core team to integrate novel genetic approaches for better prediction of drug targets. He became Genetic Analysis team leader in 2023.